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     Abstract: 
Aims: The UNTOUCHED study will assess the safety and efficacy of the subcutaneous 
implantable cardioverter defibrillator (S-ICD) in the most common cohort of patients receiving 
ICDs.  The primary goal is to evaluate the inappropriate shock (IAS) free rate in primary 
prevention patients with a reduced ejection fraction and compare with a historical control of  
transvenous ICD patients with similar programming. 
Methods and Results:  The UNTOUCHED Study is a global, multi-site, prospective, non-
randomized study with a primary endopoint of freedom from IAS at 18 months.  The lower 95% 
confidence bound of the observed incidence will be be compared to a performance goal of 
91.6%, which was derived from the IAS rate in MADIT-RIT. The secondary endpoints are,  all-
cause shock free rate at 18 months, and system and procedure related complication free rate at 
one and six months.  Enrollment of a minimum of 1100 subjects from up to 200 centers 
worldwide is planned based on power calculations of the primary and principal secondary 
endpoints. 
Conclusions: This trial will provide valuable information regarding shock therapy with the S-ICD 
in the most common group of patients receiving ICDs and will help determine the option of this 
device in a much larger cohort of patient then is presently used. 
 
Key words:  Subcutaneous ICD, primary prevention, reduced ejection fraction, inappropriate 
shock rate, safety, efficacy 
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Introduction 
The implantable cardioverter-defibrillator (ICD) is well established for either primary or 
secondary prevention of sudden cardiac death (SCD). ICDs reduce mortality and are cost-
effective in specific patient populations at increased risk of SCD (1-5).  Despite the proven 
efficacy and relative safety of traditional ICDs, there are significant risks of complications 
associated with these devices, including infection, pneumothorax, venous thrombosis, lead 
dislodgement, lead malfunction, and myocardial perforation (6, 7).  In addition, inappropriate 
shocks are associated with reduced quality of life, hospitalization and possibly mortality (8, 9).  
Long term, transvenous lead failure rate at 10 years are about 20% (10).  These short- and long-
term complications with transvenous ICDs contribute to the morbidity and mortality associated 
with these devices and may reduce utilization of this important therapy.  
     In response to complications associated with transvenous ICDs an entirely subcutaneous ICD 
(S-ICD) was developed (11).  This system consists of a pulse generator and single lead with a 
shock coil.  The pulse generator is implanted in the left lateral position between the anterior 
and mid-axillary lines near the apex of the heart.   A single lead for sensing and defibrillation is 
tunneled from the lateral pocket medially to the xiphoid process, with the distal tip near the 
manubriosternal junction(11). The S-ICD lacks functionality for bradycardia or antitachycardia 
pacing, but has novel arrhythmia discrimination algorithms (12-15).  The functional limitations 
as well as the novelty of this device likely contribute to the atypical patient populations 
receiving this device.  Compared with contemporary transvenous ICD use, S-ICD trials typically 
had younger patients with less advanced heart disease and often “niche” indications, including 
channelopathies, hypertrophic cardiomyopatly, previous ICD infection, or congenital heart 
6 
 
disease (16-23).  Although, these types of patients benefit from ICD therapy, they do not 
represent the cohorts most commonly receiving such devices. Specifically, primary prevention 
patients with left ventricular systolic dysfunction usually with heart failure represent the 
majority of patients who receive ICDs, including more than 70% of new ICD implants in the US 
(7). This is based on guidelines largely derived from the results of the MADIT II and SCD HeFT 
trials (3,4).  To assess the safety and efficacy the S-ICD in the more traditional cohort of patients 
receiving ICDs, the Understanding Outcomes with the S-ICD in Primary Prevention Patients with 
Low Ejection Fraction Study (UNTOUCHED) study is being undertaken.  
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Study Hypotheses 
The primary hypothesis of UNTOUCHED is that among primary prevention patients with a 
reduced ejection fraction, the inappropriate shock free rate will not be lower than in an 
historical control of  transvenous ICDs with similar programming (9).  
 
Study design 
The UNTOUCHED Study is a global, multi-centre, prospective, non-randomized study that will 
enroll subjects who intend to undergo de novo implantation of an EMBLEM™ or later 
generation S-ICD System (Boston  Scientific, St Paul, MN)  and have an indication for primary 
prevention of sudden cardiac death with a left ventricular ejection fraction ≤ 35%.  The key 
inclusion criteria are summarized in Table 1 and require that passing a screening 
electrocardiogram be achieved, which is standard for this device.  Programming of the device 
will be mandated with zone cut-offs at 200 bpm (Conditional Shock Zone) and 250 bpm (Shock 
Zone).  The key exclusion criteria are summarized in Table 2.  Patients with a pacing indication 
or previous history of sustained ventricular arrhythmias (secondary prevention) are excluded as 
are patients with NYHA IV CHF or end stage renal disease. Subjects will be followed semi-
annually for a minimum of 540 days (i.e., 18 months) post implant.  Occurrence of shocks from 
the ICD and occurrence of reportable events will be evaulated at each follow-up.  Figure 1 is a 
flow chart which describes the proposed study plan from first enrollment to study closure. 
 
Study Population 
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The study population consists of patients: 
•  with an ICD indication for primary prevention of sudden cardiac death and a reduced 
    ejection fraction; and 
•  who are at risk for life-threatening ventricular tachyarrhythmias and who do not 
    have symptomatic bradycardia, incessant ventricular tachycardia, or spontaneous, 
   frequently recurring ventricular tachycardia that is reliably terminated with antitachycardia 
   pacing.   
   The inclusion and exclusion criteria are further described in detail within Tables 1 and 2. 
 
Study Endpoints 
The primary endoint of UNTOUCHED is freedom from inappropriate shocks at 18 months.  The 
lower 95% confidence bound of the observed incidence will be be compared to a performance 
goal of 91.6%.  This performance goal was derived from the 18 month inappropriate shock free 
rate of 94.6% observed in ICD subjects in MADIT RIT (9, 24)  treatment Arms B and C (N= 484 ) 
plus a delta of approximately 3% to account for clinical equivalence (≈1%) and calculation of the 
lower confidence bound (≈2%). 
The secondary hypotheses include: 1) freedom from all-cause shocks at 18 months compared to 
a performance goal is 85.8% (derived in a similar way to the primary endpoint), and 2) freedom 
from system and procedure related complications at 30 days, compared to a performance goal 
of 93.8%.  An additional endpoint will be analyzed specifically to meet the Post Market Clinical 
Follow-up (PMCF) requirements for CE marking: freedom from system and procedure related 
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complications at 6 months, compared to a performance goal of 85.0%.  All study endpoints are 
listed in Table 3. 
 
In addition to the formal endpoint hypotheses, summary statistics will be calculated for pre-
specified analyses that include, but are not limited to: 
 Freedom from Appropriate Shocks at 18 months  
 All-cause mortality  
 Syncope related to VT/VF episodes  
 Implantation of a concomitant pacemaker  
 Explants and causes  
 
 
Trial Oversight 
The local ethics committees of all participating sites are required to approve the study protocol. 
Central and onsite monitoring, data review and safety oversight is provided by the sponsor, 
Boston Scientific (St Paul, MN, USA).  All shock episodes (primary endpoint related events) will 
be reviewed by an independent clinical event committee.  All device related adverse events 
regardless whether they are considered serious or not and all serious adverse events regardless 
whether device related will be reviewed. Quarterly safety review meetings will be held to 
ensure patient safety throughout the trial.  
 
Power Calculations 
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For the primary outcome of freedom from inappropriate shock, the sample size is powered to 
get a 90% confidence level with a one-sided alpha of 5%.  The expected shock free rate is 94.6% 
with a performance goal of 91.6% as noted previously. Total attrition is expected to be 15%. 
Under those assumptions a minimum of 786 subjects will be enrolled to achieve 668 patients in 
the analysis cohort.  
The secondary effectiveness outcome, freedom from all cause shocks will be compared to a 
performance goal of 85.8% with an expected shock free rate of 89.2%.  The sample size is 
powered to get a 90% confidence level with a one-sided alpha of 5%.  Total attrition is expected 
to be 15%. Under those assumptions a minimum of 1013 subjects will be enrolled to achieve 
861 patients in the analysis cohort.  
The primary safety outcome is freedom from perioperative system and procedure related 
complications (at 30 days).  This will be compared to a performance goal of 93.8% with an 
expected complication free rate of 96.6%.  The sample size is powered to get an 80% 
confidence level with a one-sided alpha of 5%.  Total attrition is expected to be 15%.  Under 
those assumptions a minimum of 471 subjects are needed in the analysis cohort.  Al least 427 
de novo S-ICD subjects who have completed the 30 day follow up at the time of the data lock 
will be included in the analysis. 
The secondary safety outcome is freedom from system and procedure related complications 
after 6 months will be compared to a performance goal of 85% with an expected complication 
free rate of 92.9%.  The sample size is powered to get an 80% confidence level with a one-sided 
alpha of 5%.  Total attrition is expected to be 15%.  Under those assumptions a minimum of 118 
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subjects are needed in the analysis cohort.  Analysis of the PMCF endpoint will be done when 
200 de novo S-ICD subjects have a follow up visit recorded at least 180 days after implant. 
 
Statistical Analyses 
Kaplan-Meier analysis will be performed for all endpoints.  The analysis will take into account 
the time from implant until the occurrence of the event.  Data from any subjects who are 
event-free will be right censored on the date of study exit.  A pooling analysis will be performed 
for patients with atrial fibrillation, who were excluded in MADIT RIT.  It is expected that results 
may differ for subjects with permanent atrial fibrillation compared to those without atrial 
fibrillation or with non-permanent atrial fibrillation.   Specifically, a likelihood ratio test from a 
logistic regression model will be conducted.  
The logistic regression model will include additional baseline covariates to attempt to adjust for 
any imbalances between baseline data.  The following baseline covariates will be considered: 
age, gender, etiology of cardiomyopathy (ischemic vs nonischemic), race, left ventricular 
ejection fraction, NYHA classification, medications, arrhythmia history, associated diseases/risk 
factors, height, weight and geography.  To determine which covariates are significantly 
associated with an endpoint, a backwards selection process will employed, using a significance 
level equal to 10%. 
If poolability is confirmed for permanent atrial fibrillation subjects, then the study results will 
be reported combining all subjects. 
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Prespecified analysis 
Summary statistics will be provided for the following secondary endpoints: 
• Freedom from Appropriate Shocks at 18 months 
• All-cause mortality 
• Syncope related to VT/VF episodes 
• Implantation of a concomitant pacemaker 
• Explants and causes (e.g., infection, need for pacing therapy, inappropriate shocks) 
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Discussion 
The role of ICDs to prevent sudden cardiac death is well established (25, 26).  The populations 
implanted with the S-ICD to date have largely been skewed towards younger patients with less 
structural heart disease and fewer co-morbidities.  Although the device has performed well in 
these groups, suitability in the larger groups of eligible patients still remains incompletely 
understood.  For this reason, UNTOUCHED was designed to understand better the safety and 
efficacy of the S-ICD in the most common cohort undergoing ICD implantation in North America 
and Europe, namely primary prevention patients with a reduced ejection fraction 
The S-ICD is a newer device that has both advantages and disadvantages compared with 
transvenous devices (27, 28).  Specifically, implantation of this system avoids many of the 
complications associated with transvenous leads, such as pneumothorax, cardiac tamponade 
and bacteremia. Early and mid-term results suggest a very low incidence of lead failure (15, 19).   
In general, ICD procedural outcomes improve with number of implants performed by physicians 
(29).  This has also been observed for the S-ICD (30), so only centers that have experience with 
this device will be included.   The potential limitations of the S-ICD include the lack of 
antitachycardia pacing and it has only very short duration post-shock bradycardia pacing.  Given 
these features, the S-ICD has clearly filled important voids where transvenous leads are 
relatively or absolutely contraindicated, such as patients with a lack of venous access or those 
with systemic infection (22, 31, 32).   
The S-ICD has a unique discrimination algorithm that uses a number of features including 
template matching, rate, electrogram width and waveform stability to classify arrhythmias.  A 
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head to head comparison of this algorithm with conventional ICD algorithms for a series of 
induced supraventricular arrhythmias showed superiority of the S-ICD system (13).  However, 
early clinical experience showed higher rates of inappropriate shocks, although this was rarely 
due to errors in discrimination of supraventricular arrhythmias (19). Rather, such shocks are 
most commonly due to T-wave oversensing and the failure to activate the conditional zone of 
the device, where the discrimination algorithms are used (33).  More recently, the algorithm 
has been modified to reduce further the risk of oversensing (14, 34).  UNTOUCHED will be the 
first study of the S-ICD to have prescriptive programming requiring activation of the conditional 
zone with no therapies delivered for rates < 200 bpm. This is consistent with the high rate arm 
of MADIT RIT which is the study used to establish the performance goal for all shock endpoints.  
The most rigorous scientific approach to assess the role of the S-ICD among patients with 
primary prevention indications and a reduced left ventricular ejection fraction is to perform a 
randomized trial.  PRAETORIAN is such a randomized trial comparing the S-ICD and transvenous 
systems and is currently recruiting patients (35).  However, that study does not restrict subjects 
by ejection fraction or indication, but simply requires that patients be appropriate for either 
device.  This will likely result in an atypical cohort of patients as with other S-ICD trials, despite 
the importance of this trial as a randomized study.  To repeat such a study in the low ejection 
fraction, primary prevention population would require a very large study and many years to 
complete.  Therefore, it was decided best to compare the results with an historical control.  
MADIT RIT was chosen as the control group for several reasons. First, the programming is 
similar to that used in the S-ICD. Specifically, high rates and relatively long detection durations 
were used In MADIT RIT (9, 24). The marked reduction in inappropriate therapies established 
15 
 
such programming as optimal and is now recommended in consensus documents for primary 
prevention patients (36).   Thus, UNTOUCHED will compare S-ICD outcomes with a very 
aggressive programming strategy from clinical trials which resulted in a marked reduction in 
shocks.  This will serve to minimize the risk that if the performance measures are met that this 
will still be considered inadequate results to justify the use of the S-ICD in contemporary 
populations.  
In summary, UNTOUCHED is a prospective open labeled study that will be the first trial of the S-
ICD to study the device in the primary prevention population with a reduced ejection fraction. 
Moreover, it is also the first S-ICD trial with prescriptive programming aimed to demonstrate 
the safety of using the discrimination algorithm at rates as up to 250 bpm. The results of this 
trial will provide an accurate estimate of shock therapy with this device in the most common 
group of patients receiving ICDs and will help determine the option of this device in a much 
larger cohort of patient then is presently used in clinical practice.  
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Tables 
Table 1: Inclusion Criteria 
 Patient with ischemic or non-ischemic heart disease who meets current guidelines 
for ICD therapy and intends to undergo a de novo implant procedure for an 
EMBLEM™ S-ICD  (or newer generation BSC S-ICD) 
 Left ventricular ejection fraction ≤ 35% 
 A passing EMBLEM™ S-ICD  (or newer generation BSC S-ICD) screening ECG 
 Patient ≥ 21 years of age willing and capable of giving informed consent  
 Patient willing and capable of complying with follow-up visits 
  ICD, implantable cardioverter defibrillator, BSC, Boston Scientific Corporation, S-ICD, 
subcutaneous implantable cardioverter defibrillator, ECG, electrocardiogram. 
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Table 2: Exclusion Criteria 
 Patient with a history of spontaneous sustained VT or VF 
 Patient with bradycardia pacing indication 
 Patient eligible and planned for cardiac resynchronization therapy 
 Patient with a previous S-ICD or a previous transvenous pulse generator 
(pacemaker or defibrillator) 
 Patient in NYHA Class IV within 90 days before enrolment 
 Patient with life expectancy shorter than 18 months due to any concomitant  
medical condition 
 Patient receiving hemodialysis within 180 days of enrolment 
 Patient unwilling or unable to cooperate with the protocol 
 
 VT/VF, ventricular tachyarrhythmia/ ventricular fibrillation, S-ICD, subcutaneous implantable 
cardioverter defibrillator, NYHA, New York Heart Association classification. 
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 Table 3: UNTOUCHED Study Endpoint Hypotheses 
Primary 
Endpoint 
The Inappropriate Shock Free Rate at 18 months exceeds the performance 
goal of 91.6%.  
Secondary 
Endpoint 
The All-Cause Shock Free Rate at 18 months exceeds the performance goal 
of 85.8%  
Secondary 
Endpoint 
The System and Procedure Related Complication Free Rate at 1 month 
exceeds the performance goal of 93.8%.  
PMCF Endpoint The System and Procedure Related Complication Free Rate at 6 months 
exceeds the performance goal of 85.0%.  
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Figures 
Figure 1: UNTOUCHED Study Design 
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Figure Legends 
Figure 1: Flow chart of the UNTOUCHED study design from enrollment of first patient to study 
closure. The duration of the study is expected to be approximately 58 months.  PMCF: Post 
Market Clinical Follow-up Endpoint, CRT: Cardiac Re-synchronization Therapy, VT/VF: 
Ventricular Tachycardia/Ventricular Fibrillation, LVEF: Left Ventricular Ejection Fraction, S-ICD: 
Subcutaneous Implantable Cardioverter Defibrillator, ECG: Electrocardiogram. 
